Active Not Recruiting PHASE3 INTERVENTIONAL 5-arm NCT05463731

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease

Sponsor: Eli Lilly and Company

Conditions Alzheimer's Disease

Interventions Placebo Remternetug (IV) Remternetug (SC)

Updated 24 times since 2022 Last updated: Apr 23, 2025 Started: Aug 1, 2022 Primary completion: Apr 24, 2024 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05463731, this PHASE3 trial focuses on Alzheimer's Disease and remains ongoing. Sponsored by Eli Lilly and Company, it has been updated 24 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

24 versions recorded

May 2025 — Present [monthly]

Active Not Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 19 earlier versions

Nov 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE3
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlantis, United States , Austin, United States , Aventura, United States , Basalt, United States , Beaumont, United States , Bellevue, United States , Bolivar, United States , Boulder, United States , Bunkyo-ku, Japan and 62 more locations